Punicalagins (Pomegranate Ellagitannins) and prostate

What 2 graded rows on punicalagins (pomegranate ellagitannins) agree on for prostate, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Punicalagins (Pomegranate Ellagitannins) page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Punicalagins (Pomegranate Ellagitannins) page, with its PubMed record.

Supplement

Punicalagins (Pomegranate Ellagitannins) Choose another

2 rows · 174 people

They agree: both rows found no difference.

No difference

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside.

From the rows

The best-graded row, grade C, is a randomized trial of 70 people (2013) and found no difference.

The rows run from 70 to 104 people, published in 2013: 2 single studies.

2 no difference

Grade CProstate tissue oxidative stress before surgery · No difference
RCT · n 70 · 2013 · Men with prostate cancer awaiting radical prostatectomy
2 tablets a day · Up to 4 weeks
Benign tissue 8-OHdG was 16% lower with POMx (P = 0.095), not statistically significant; Ki67, NF-kB, pS6 kinase and PSA changes did not differ. Urolithin A was detected in prostate tissue in 21 of 33 men on POMx vs 12 of 35 on placebo.
Row on the Punicalagins (Pomegranate Ellagitannins) page · PubMed 23985577 (opens PubMed)
Grade DPSA doubling time: 1 g vs 3 g extract · No difference
RCT · n 104 · 2013 · Men with rising PSA after initial therapy for localized prostate cancer, no metastases
1 g or 3 g a day · Up to 18 months
Median PSA doubling time lengthened from 11.9 to 18.5 months overall, with no difference between doses (P = 0.554); without a placebo arm the change cannot be attributed to the extract. Diarrhoea occurred in 1.9% (1 g) and 13.5% (3 g).
Row on the Punicalagins (Pomegranate Ellagitannins) page · PubMed 22689129 (opens PubMed)